Refine
Document Type
- Article (22)
Language
- English (22)
Has Fulltext
- yes (22)
Is part of the Bibliography
- no (22)
Keywords
- liver transplantation (3)
- Acute myeloid leukemia (2)
- Aspergillus (2)
- Methicillin-resistant Staphylococcus aureus (2)
- Neutropenia (2)
- multidrug resistance (2)
- AML (1)
- Antibiotic steward-ship (1)
- Antibiotics (1)
- Antiretroviral therapy (1)
- Aspergillus species (1)
- Bloodstream infection (1)
- Bloodstream infections (1)
- Burkholderia arboris (1)
- CDI (1)
- Cancer (1)
- Candida (1)
- Chemotherapy (1)
- Cluster (1)
- Culture positive (1)
- DST (1)
- De-isolation (1)
- Death rates (1)
- Drug susceptibility testing (1)
- ESBL (1)
- Enterobacteriaceae (1)
- Fevers (1)
- Francisella tularensis (1)
- Francisella tularensis subspecies holarctica (1)
- Fusarium (1)
- Gram negative bacteria (1)
- HIV (1)
- Hematology (1)
- Hematopoietic stem cell transplantation (1)
- Hepatocellular carcinoma (1)
- Hospitals (1)
- Induction chemotherapy (1)
- Infection (1)
- Intensive care units (1)
- Liver cancer (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- Multidrug-resistant organisms (1)
- Multivariate analysis (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- NK-92 (1)
- NTM (1)
- Non-tuberculous mycobacteria (1)
- Nontuberculous mycobacteria (1)
- Oncology (1)
- Open pulmonary tuberculosis (1)
- Opportunistic infections (1)
- PD-L1 (1)
- Protease inhibitor therapy (1)
- Pseudomonas aeruginosa (1)
- Respiratory infections (1)
- Sputum smear-negative (1)
- Stenotrophomonas maltophilia (1)
- Survival (1)
- TB-therapy (1)
- Tularemia (1)
- VRE (1)
- Zoonosis (1)
- antibiotic therapy (1)
- antibiotic treatment (1)
- antifungal activity (1)
- antimicrobial stewardship (1)
- ascites (1)
- biliary stricture (1)
- bronchial epithelium (1)
- burkholderia (1)
- burkholderia cepacia complex infections (1)
- carbapenem resistance (1)
- catheter (1)
- cirrhosis (1)
- clonal transfer (1)
- co-infection (1)
- cyclosporin A (1)
- cystic fibrosis (1)
- cytotoxic T cells (1)
- death rates (1)
- disease outbreaks (1)
- electrophoresis (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- epidemiology (1)
- epididymitis (1)
- familial amyloid nephropathy with urticaria and deafness (1)
- fluorescence in situ hybridization (FISH) (1)
- fungal sinusitis (1)
- gel (1)
- genome (1)
- growth inhibition (1)
- immunosuppressive agent (1)
- infection control (1)
- infections (1)
- invasive fungal infection (1)
- liver (1)
- liver cirrhosis (1)
- medical device (1)
- medical risk factors (1)
- methylprednisolone (1)
- microbial colonization (1)
- mixed infection (1)
- mouthwash (1)
- mouthwash solution (1)
- mucormycetes (1)
- mycophenolic acid (1)
- natural killer cell (1)
- outbreak (1)
- pseudomonas aeruginosa (1)
- pulsed-field (1)
- reactive oxygen species (1)
- recurrent cholangitis (1)
- respiratory infections (1)
- rhinovirus (1)
- risk score (1)
- screening routine (1)
- sepsis (1)
- short-course antibiotic therapy (1)
- suprapubic catheter (1)
- transmission (1)
- transurethral catheter (1)
- viability (1)
- whole-genome sequencing (1)
Institute
- Medizin (22)
Patients with acute myeloid leukemia (AML) are often exposed to broad-spectrum antibiotics and thus at high risk of Clostridioides difficile infections (CDI). As bacterial infections are a common cause for treatment-related mortality in these patients, we conducted a retrospective study to analyze the incidence of CDI and to evaluate risk factors for CDI in a large uniformly treated AML cohort. A total of 415 AML patients undergoing intensive induction chemotherapy between 2007 and 2019 were included in this retrospective analysis. Patients presenting with diarrhea and positive stool testing for toxin-producing Clostridioides difficile were defined to have CDI. CDI was diagnosed in 37 (8.9%) of 415 AML patients with decreasing CDI rates between 2013 and 2019 versus 2007 to 2012. Days with fever, exposition to carbapenems, and glycopeptides were significantly associated with CDI in AML patients. Clinical endpoints such as length of hospital stay, admission to ICU, response rates, and survival were not adversely affected. We identified febrile episodes and exposition to carbapenems and glycopeptides as risk factors for CDI in AML patients undergoing induction chemotherapy, thereby highlighting the importance of interdisciplinary antibiotic stewardship programs guiding treatment strategies in AML patients with infectious complications to carefully balance risks and benefits of anti-infective agents.
Molecular surveillance of carbapenem-resistant gram-negative bacteria in liver transplant candidates
(2021)
Background: Carbapenem-resistant Gram-negative bacteria (CRGN) cause life-threatening infections due to limited antimicrobial treatment options. The occurrence of CRGN is often linked to hospitalization and antimicrobial treatment but remains incompletely understood. CRGN are common in patients with severe illness (e.g., liver transplantation patients). Using whole-genome sequencing (WGS), we aimed to elucidate the evolution of CRGN in this vulnerable cohort and to reconstruct potential transmission routes.
Methods: From 351 patients evaluated for liver transplantation, 18 CRGN isolates (from 17 patients) were analyzed. Using WGS and bioinformatic analysis, genotypes and phylogenetic relationships were explored. Potential epidemiological links were assessed by analysis of patient charts.
Results: Carbapenem-resistant (CR) Klebsiella pneumoniae (n=9) and CR Pseudomonas aeruginosa (n=7) were the predominating pathogens. In silico analysis revealed that 14/18 CRGN did not harbor carbapenemase-coding genes, whereas in 4/18 CRGN, carbapenemases (VIM-1, VIM-2, OXA-232, and OXA-72) were detected. Among all isolates, there was no evidence of plasmid transfer-mediated carbapenem resistance. A close phylogenetic relatedness was found for three K. pneumoniae isolates. Although no epidemiological context was comprehensible for the CRGN isolates, evidence was found that the isolates resulted of a transmission of a carbapenem-susceptible ancestor before individual radiation into CRGN.
Conclusion: The integrative epidemiological study reveals a high diversity of CRGN in liver cirrhosis patients. Mutation of carbapenem-susceptible ancestors appears to be the dominant way of CR acquisition rather than in-hospital transmission of CRGN or carbapenemase-encoding genetic elements. This study underlines the need to avoid transmission of carbapenem-susceptible ancestors in vulnerable patient cohorts.